UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ⊠	
Filed by a Party other than the Registrant \square	
Check the appropriate box:	
☐ Preliminary Proxy Statement	
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))	
☐ Definitive Proxy Statement	
☑ Definitive Additional Materials	
□ Soliciting Material Pursuant to §240.14a-12	
Soliciting Material Pursuant to §240.14a-12 IOVANCE BIOTHERAPEUTICS, INC.	
Ç v	
IOVANCE BIOTHERAPEUTICS, INC.	
IOVANCE BIOTHERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter)	
IOVANCE BIOTHERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) Payment of Filing Fee (check the appropriate box):	



IOVANCE BIOTHERAPEUTICS, INC.

2024 Annual Meeting Vote by June 10, 2024 11:59 PM ET



V50880-P10600

You invested in IOVANCE BIOTHERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 11, 2024.

Get informed before you vote

View the Annual Report and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 28, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number



Vote Virtually at the Meeting*

June 11, 2024 11:00 AM EDT

Vote virtually at: https://www.cstproxy.com/iovance/2024

^{*}Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

IOVANCE BIOTHERAPEUTICS, INC. 2024 Annual Meeting Vote by June 10, 2024 11:59 PM ET

ting Items	Board Recommends
Election of Directors	
Nominees:	
01) Iain Dukes, D. Phil. 02) Athena Countouriotis, M.D. 03) Ryan Maynard 04) Wayne P. Rothbaum 05) Frederick G. Vogt, Ph.D., J.D. 06) Michael Weiser, M.D., Ph.D. 07) Wendy Yarno	⊘ For
To approve, by non-binding advisory vote, the compensation of our named executive officers;	⊘ For
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;	⊘ For
To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from the 2014 Equity Incentive Plan; and	⊘ For
To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 1,400,000 shares to 1,900,000 shares.	For
TE: Such other business as may properly come before the meeting or any adjournment thereof.	
	Nominees: 01) Iain Dukes, D. Phil. 02) Athena Countouriotis, M.D. 03) Ryan Maynard 04) Wayne P. Rothbaum To approve, by non-binding advisory vote, the compensation of our named executive officers; To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024; To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from the 2014 Equity Incentive Plan; and To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 1,400,000 shares to 1,900,000 shares.